replicateBE
Average Bioequivalence with Expanding Limits (ABEL)
Performs comparative bioavailability calculations for Average Bioequivalence with Expanding Limits (ABEL). Implemented are 'Method A' / 'Method B' and the detection of outliers. If the design allows, assessment of the empiric Type I Error and iteratively adjusting alpha to control the consumer risk. Average Bioequivalence - optionally with a tighter (narrow therapeutic index drugs) or wider acceptance range (South Africa: Cmax) - is implemented as well.
- Version1.1.3
- R versionunknown
- LicenseGPL (≥ 3)
- Needs compilation?No
- Reference manual
- Last release05/02/2022
Documentation
Team
Helmut Schütz
Detlew Labes
Show author detailsRolesContributorMichael Tomashevskiy
Show author detailsRolesContributor
Insights
Last 30 days
Last 365 days
The following line graph shows the downloads per day. You can hover over the graph to see the exact number of downloads per day.
Data provided by CRAN
Binaries
Dependencies
- Imports5 packages
- Suggests4 packages